<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04627051</url>
  </required_header>
  <id_info>
    <org_study_id>20-5673</org_study_id>
    <nct_id>NCT04627051</nct_id>
  </id_info>
  <brief_title>Atherectomy and Drug Coated Balloon for the Treatment of Arterio-Venous Graft Stenosis</brief_title>
  <official_title>A Prospective, Single-Centre Study Investigating the Clinical Use and Safety of the Jetstream Atherectomy With Drug Coated Balloon (Ranger) for the Treatment of Dysfunctional Arterio-Venous Graft Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This single-centre, single-arm, prospective study will enroll 30 subjects presenting with&#xD;
      clinical and hemodynamic abnormalities in arteriovenous graft (AVG) in the arm. Subjects will&#xD;
      be treated with the Jetstream™ atherectomy device and Ranger™ Drug Coated Balloons (DCB).&#xD;
      Subjects will be followed up clinically via office visit or phone visit at 6 and 12 months&#xD;
      post procedure. This study is to demonstrate safety and assess the clinical use and outcomes&#xD;
      of the Jetstream ™atherectomy device and Ranger™ DCB for the treatment of dysfunctional AV&#xD;
      graft.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 12, 2020</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Treatment of Jetstream™ atherectomy device and Ranger ™ drug coated balloons</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target Lesion Primary Patency (TLPP) through 6 months</measure>
    <time_frame>within 6 months post intervention</time_frame>
    <description>50% re-stenosis of the target lesion</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Dysfunctional Arterial-venous Grafts</condition>
  <arm_group>
    <arm_group_label>Dysfunction AV graft</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dysfunctional AV graft stenosis treated with atherectomy and drug coated balloon angioplasty</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Atherectomy and balloon angioplasty</intervention_name>
    <description>Atherectomy and balloon angioplasty of arterial-venous graft stenosis</description>
    <arm_group_label>Dysfunction AV graft</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or non-pregnant, non-breastfeeding female ≥18 years of age;&#xD;
&#xD;
          -  Subject is willing to provide informed consent, and is willing to comply with the&#xD;
             protocol-required follow up visits;&#xD;
&#xD;
          -  Target lesion must be a mature arteriovenous graft presenting with any clinical,&#xD;
             physiological or hemodynamic abnormalities warranting angiographic imaging as defined&#xD;
             in the K/DOQI guidelines;&#xD;
&#xD;
          -  Subject has a target lesion at the venous anastomosis of the AVG;&#xD;
&#xD;
          -  Successful crossing of the stenosis;&#xD;
&#xD;
          -  Each lesion length is ≤20mm, which may include tandem lesions that are ≤20mm apart&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject is currently participating in an investigational drug or device study which&#xD;
             has not yet reached its primary endpoint or was previously enrolled into this study;&#xD;
&#xD;
          -  Subject has a non-controllable allergy to contrast;&#xD;
&#xD;
          -  Subject has more than 3 lesions in the access circuit requiring intervention;&#xD;
&#xD;
          -  Target lesion diameter &gt;10mm;&#xD;
&#xD;
          -  A thrombosed access or an access with a thrombosis treated ≤30 days prior to the index&#xD;
             procedure;&#xD;
&#xD;
          -  Prior surgical interventions of the access site ≤30 days before the index procedure;&#xD;
&#xD;
          -  Target lesion is located within a bare metal or covered stent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kong Teng Tan, MD</last_name>
    <phone>416-340-4800</phone>
    <phone_ext>6166</phone_ext>
    <email>kongteng.tan@uhn.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 9, 2020</study_first_submitted>
  <study_first_submitted_qc>November 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2020</study_first_posted>
  <last_update_submitted>March 10, 2021</last_update_submitted>
  <last_update_submitted_qc>March 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

